Multidimensional Omics Analysis in Malignant Pleural Mesothelioma (OMIM)
2026年4月24日 更新者:Azienda USL Reggio Emilia - IRCCS
Multidimensional Omics and Functional Approaches to Improve Immunotherapy Efficacy in Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is a rare and incurable cancer.
Most patients are diagnosed with unresectable disease for which treatment options are limited.
The lack of prognostic biomarkers further complicates the decision-making.
Recently, the introduction of immune checkpoint inhibitors (ICIs) has marked a shift but has failed to produce significant benefits for a large proportion of patients.
Maximizing the efficiency of ICIs and developing new protocols to improve drug efficacy is the best possible strategy for improving the life expectancy and quality of life of patients with MPM.
This study aims to characterize the organization of the immune system infiltrating mesothelioma and the dynamics of its interaction with the tumor.
The rationale is that deciphering this complexity will help improve our understanding of the mechanisms underlying this disease and provide a new tool to optimize the use of ICIs in these patients.
研究概览
地位
招聘中
详细说明
Malignant Pleural Mesothelioma (MPM) is a rare and highly aggressive malignancy characterized by poor prognosis and limited therapeutic options.
Most patients are diagnosed at an advanced, unresectable stage, with a median overall survival of approximately one year.
Although the introduction of immune checkpoint inhibitors (ICIs) has represented a significant advancement, a substantial proportion of patients fail to derive meaningful clinical benefit.
The lack of reliable prognostic and predictive biomarkers, together with marked molecular heterogeneity and limited understanding of disease biology, significantly hampers the development of effective therapeutic strategies.
MPM is strongly associated with chronic inflammation driven by asbestos exposure, which profoundly alters the pleural microenvironment.
Within this context, tumor cells and immune cells engage in dynamic and reciprocal interactions, generating a complex ecosystem that promotes disease progression and the emergence of aggressive phenotypes.
The ability of tumor cells to modulate immune system activity is considered a key driver of MPM pathogenesis.
This study aims to comprehensively characterize the organization of the tumor-infiltrating immune system and the dynamic interactions between tumor and immune cells.
To achieve this goal, an integrative and multidimensional omics approach will be employed to generate a high-resolution map of MPM ecosystem and to identify novel biomarkers and potential therapeutic targets.
This is an exploratory, non-interventional, non-pharmacological study with both prospective and retrospective components, conducted exclusively on biological samples collected during routine clinical practice.
The study population will be structured into three complementary cohorts.
A training prospective cohort (C1 - Training Set) including newly diagnosed MPM patients from whom fresh frozen (FF) tumor samples will be collected from diagnostic biopsies, surgical resections, or malignant pleural effusions, enabling in-depth characterization of the tumor and immune microenvironment.
A validation independent retrospective cohort (C2 - Validation Set) including MPM samples collected between 2015 and 2022 and used to validate findings obtained in the training cohort.
A nested cohort within C1 (C3 - HITHOC Set) that will include patients undergoing surgery combined with hyperthermic intrathoracic chemotherapy (HITHOC), allowing investigation of tumor-immune interactions and treatment response mechanisms in this specific clinical setting.
By integrating data across these three cohorts, the study aims to identify immune-related markers associated with tumor aggressiveness, discover novel targets for next-generation immunotherapies, and characterize mechanisms underlying response to chemotherapy, with particular focus on the HITHOC setting.
Expected outcomes include improved understanding of MPM biology, identification of novel biomarkers, and optimization of immunotherapy strategies, ultimately contributing to the development of more effective and personalized treatments for patients affected by this disease.
研究类型
观察性的
注册 (估计的)
300
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Alessia Ciarrocchi, PhD
- 电话号码:0522/295668
- 邮箱:alessia.ciarrocchi@ausl.re.it
学习地点
-
-
-
Catania、意大利
- 招聘中
- Azienda Ospedaliera Universitaria Policlinico Rodolico San Marco di Catania
-
接触:
- Giacomo Cusumano, MD PhD
- 电话号码:095 3781175
- 邮箱:giacomo.cusumano@unict.it
-
Naples、意大利
- 招聘中
- Azienda Ospedaliera Universitaria Luigi Vanvitelli, Napoli
-
接触:
- Alfonso Fiorelli, MD PhD
- 邮箱:alfonso.fiorelli@unicampania.it
-
Reggio Emilia、意大利
- 招聘中
- Azienda USL IRCCS di Reggio Emilia
-
接触:
- Alessia Ciarrocchi, PhD
- 电话号码:0522/295668
- 邮箱:alessia.ciarrocchi@ausl.re.it
-
首席研究员:
- Alessia Ciarrocchi, PhD
-
Roma、意大利
- 招聘中
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
-
接触:
- Filippo Lococo, MD
- 电话号码:06 8881 8881
- 邮箱:filippo.lococo@policlinicogemelli.it
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
取样方法
概率样本
研究人群
The study population includes patients diagnosed with Malignant Pleural Mesothelioma (MPM).
Both prospective and retrospective cohorts will be included to ensure a comprehensive and biologically representative characterization of the disease.
Eligible patients will have histologically confirmed MPM and available tumor biological samples obtained from diagnostic biopsies, surgical resections, or pleural effusions.
Samples will include both fresh frozen (FF) material and formalin-fixed paraffin-embedded (FFPE) archival specimens.
描述
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the study
- Aged > 18 years
- Patients with histologically confirmed diagnosis of MPM
- Availability of biological material
- Clinical indicatio of eligibility for HITOCH protocol (only for C3 cohort)
Exclusion Criteria:
- Active current infection
- Autoimmune disease
- Women in childbearing age not able to exclude pregnancy
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
C1 - Training set
A prospective cohort of MPM patients enrolled.
Analyses will be performed on fresh frozen (FF) tumor samples derived from diagnostic biopsies, surgical resections, or malignant pleural effusions (MPE).
|
|
C2 - Validation Set
An independent retrospective cohort of MPM samples collected between 2015 and 2022.
This cohort will serve to validate findings obtained in the training set.
|
|
C3 - HITHOC Set
An prospective cohort of patients undergoing surgery combined with hyperthermic intrathoracic chemotherapy (HITHOC).
This cohort will enable investigation of tumor-immune interactions and treatment response mechanisms in this specific clinical setting.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
High-resolution mapping of the organization of the tumor-infiltrating immune system in MPM
大体时间:36 months
|
Characterization of the composition, functional state, and spatial organization of tumor-infiltrating immune cells using integrated bulk, single-cell, and spatial transcriptomic analyses on tumor tissues and malignant pleural effusions.
|
36 months
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Immune-related gene signatures by whole transcriptome sequencing (normalized counts).
大体时间:36 months
|
36 months
|
|
Immune-phenotyping by multiple parametric cytofluorimetry (cell counts)
大体时间:36 months
|
36 months
|
|
Analysis of circulating cytokines by bead-based multiplex assays (concentration micrograms/microliter)
大体时间:36 months
|
36 months
|
|
Association between immune features and clinical outcomes by correlation between gene expression (normalized, cell counts and/or concentration counts) and overall survival (months)
大体时间:36 months
|
36 months
|
|
Association between transcriptional signatures and pathological response to chemotherapy by correlation of gene expression (normalized counts) and response to therapy (time to progression -months)
大体时间:36 months
|
36 months
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Alessia Ciarrocchi、Azienda USL - IRCCS di Reggio Emilia
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2024年8月30日
初级完成 (实际的)
2024年8月30日
研究完成 (估计的)
2027年2月28日
研究注册日期
首次提交
2026年4月16日
首先提交符合 QC 标准的
2026年4月24日
首次发布 (实际的)
2026年5月1日
研究记录更新
最后更新发布 (实际的)
2026年5月1日
上次提交的符合 QC 标准的更新
2026年4月24日
最后验证
2026年4月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.